home | contact | site map | terms

• Introducing Coartem®   
  Dispersible for children
  • Product Monograph
  • Key Publications
  • Coartem^® Dispersible Film
  • Congress Highlighters
  • Package Leaflet
• Coartem®              
  
  • Dosage Card
  • Product Monograph
  • Key Publications
  • Congress Highlighters
  • Package Leaflet
• News/         
  Media room
  • Press Releases
  • Fact Sheets
  • Visual Material
  • Publications
  • Useful Links
• Training         
  Materials
  • Healthworker Job Aid
• Calendar         
  of Events
• About Us - Novartis         
  Malaria Initiatives
  • Malaria Initiatives Brochure
    • Version française
    • Deutsche Version
    • Versão portuguesa
  • Malaria Initiatives Online
  • Fighting Malaria Film
    • Version française
    • Deutsche Version
    • Versión española
• Useful links

Press releases

The latest Coartem^® and Coartem^® Dispersible news

	Novartis delivers 250,000,000th Coartem® treatment and becomes first healthcare company to join United Against Malaria partnership July 2009
	Scientists who developed Novartis Coartem® and Glivec® receive 2009 ''European Inventor of the Year'' awards May 2009
	Coartem® receives FDA approval becoming first artemisinin-based combination treatment (ACT) for malaria in the US April 8 2009
	Novartis and Medicines for Malaria Venture launch Coartem® Dispersible, the first ACT developed for children suffering from malaria Jan 2009
	Novartis announces 20% average reduction in price of malaria drug Coartem® to further accelerate access in malaria-endemic regions April 2008

DISCLAIMER FOR ARCHIVES

The information [in our Archives] was factually accurate on the date of publication. This information remains on our website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon this information as current or accurate after their publication dates.